Asian Spectator


The Times

.

Josh Ferris and Justine Guerard Triumph at the 32nd Laguna Phuket Triathlon, Asia’s Longest-Running Triathlon

Australia’s Ferris and France’s Guerard conquer Phuket’s iconic resort racecourse, as international athletes battle for USD 20,000 in prize money.PHUKET, THAILAND – Media OutR...

China Mobile Hong Kong and Zung Fu Join Hands in Fostering A Quality Living Experience in The Greater Bay Area

HONG KONG, CHINA - Media OutReach - November 29, 2018 - With the successful launch of Hong Kong-Zhuhai-Macau Bridge, the flow of people, logistics, capital and informatio...

PolyU Design Announces New Research Centre of Future Caring Mobility and Opportunity for Partnerships

HONG KONG SAR - Media OutReach - 19 August 2022 - The Hong Kong Polytechnic University School of Design (PolyU Design) has announced the establishment of the Research Centre of Future Carin...

Lexus Partners with the Maverick Academy to Drive Culinary Excellence in Latest Cooking Competition

SINGAPORE - Media OutReach Newswire - 28 October 2024 - This October, Lexus Asia announces their partnership with AR Asia Production to launch an exciting gastronomy series The Maverick Aca...

Parallel Wireless Partners with Inatel, Telecom Infra Project ...

NASHUA, N.H., April 14, 2022 /PRNewswire-AsiaNet/ -- --Enabling state-of-the-art 4G and 5G broadband communications and new applicationsParallel Wireless, Inc., the U.S.-based Open RAN leade...

CGTN: Why China entrusts youth with the country's future

BEIJING, May 10, 2022 /PRNewswire-AsiaNet/ -- What are today's Chinese youth really like? They are confident, hopeful and responsible – that's the answer given by the country's first w...

Lenovo Unleashes AI-Powered Creativity and Productivity Devices and Solutions at CES 2024

Lenovo™ strengthens its portfolio and vision of AI for All with AI PCs and other powerful innovations HONG KONG SAR - Media OutReach Newswire - 12 January 2024 - Today at CES®...

TIAS Releases Final Report on Project to Support Formation of ...

TSUKUBA, Japan, Mar. 22, 2021 /Kyodo JBN-AsiaNet/ -- - Culminating Seven-year Efforts to Develop Int'l Sport Community and Achievements -Tsukuba International Academy for Sport Studies (TIAS...

Surgere: AutoSphere Gains Altitude – Faster Than Ever

CLEVELAND; TOKYO; ANTWERP, Belgium; AGUASCALIENTES, Mexico, July 21, 2020 /PRN-AsiaNet/-- The Surgere Automotive Supply Chain Community has reached record numbers. The community's amazing gr...

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

TOKYO, Mar 26, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL).

This application is based on data from a multicenter, open-label, single-arm Phase II clinical study (study 205) conducted in Japan for patients with relapsed or refractory CTCL or PTCL to evaluate the efficacy and safety of this agent.

This study achieved the primary endpoint and exceeded a predetermined threshold with statistical significance: the objective response rate (ORR) of CTCL and PTCL patients in total (n=36) was 36.1% (95% confidence interval (CI): 20.8-53.8). The ORRs of each subtype were 31.6% (95% CI:12.6-56.6) for CTCL (n=19) and 41.2% (95%CI: 18.4-67.1) for PTCL (n=17).

The five most frequent adverse events observed in this study were increased aspartate aminotransferase (AST) (89.2%), increased alanine aminotransferase (ALT) (86.5%), hypoalbuminaemia (70.3%), lymphopenia (70.3%), and pyrexia (51.4%).

Denileukin diftitox (genetic recombinant) is a fusion protein of the receptor-binding portion of interleukin-2 (IL-2) and diphtheria toxin that specifically binds to the IL-2 receptor on the surface of tumoral lymphocyte. The antitumor effect of denileukin diftitox depends on the intracellular delivery of diphtheria toxin which inhibits protein synthesis and induces cell death. The agent has been evaluated as a drug with high medical need by the "Study Group for Unapproved Drugs/Off-Label Drugs for High Medical Needs"(1), and Eisai has been requested to develop it by the Ministry of Health, Labour and Welfare.

Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals.

(1) The Study Group set up within the Ministry of Health, Labour and Welfare with the purpose of contributing to enhancing the development of drugs and indications that have not been approved in Japan (unapproved drugs/off-label drugs) by pharmaceutical companies. In addition to evaluating the medical needs of unapproved drugs/off-label drugs, their responsibilities include evaluating the applicability of the drug to an Application with Public Knowledge, and the adequacy of additional clinical studies that need to be conducted for filing applications for approval, and so on.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegalmarsbahisuk casinos not on gamstophttps://www.capitolcitycinema.org/grandpashabet resmi girişStreamEastStreamEastjojobet